High-Grade Serous Fallopian Tube Cancer

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Niraparib
FDA (1)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Niraparib
EMA (1) FDA (2) HSE (2)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	HRD	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
FDA (1)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
FDA (1)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
FDA (1)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
FDA (1)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Rucaparib
EMA (1) FDA (1)	FOLR1 positive	High-Grade Serous Fallopian Tube Cancer	Mirvetuximab soravtansine